47.9 USD
-0.59 (-1.22%)
47.9 USD
0 (0%)
Overall HROW gets a fundamental rating of 5 out of 10. We evaluated HROW against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HROW get a neutral evaluation. Nothing too spectacular is happening here. HROW shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
- HROW had positive earnings in the past year.
- In the past year HROW had a positive cash flow from operations.
- In the past 5 years HROW always reported negative net income.
- In multiple years HROW reported negative operating cash flow during the last 5 years.
1.2 Ratios
- The Return On Assets of HROW (-1.37%) is better than 74.87% of its industry peers.
- Looking at the Return On Equity, with a value of -10.60%, HROW is in the better half of the industry, outperforming 72.77% of the companies in the same industry.
- The Return On Invested Capital of HROW (7.48%) is better than 85.34% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for HROW is significantly below the industry average of 12.84%.
- The last Return On Invested Capital (7.48%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.37% | ||
| ROE | -10.6% | ||
| ROIC | 7.48% |
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
1.3 Margins
- HROW has a better Operating Margin (11.27%) than 83.77% of its industry peers.
- HROW's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 74.56%, HROW belongs to the top of the industry, outperforming 81.15% of the companies in the same industry.
- In the last couple of years the Gross Margin of HROW has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.27% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% |
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HROW is destroying value.
- Compared to 1 year ago, HROW has more shares outstanding
- The number of shares outstanding for HROW has been increased compared to 5 years ago.
- HROW has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 4.05 indicates that HROW is not in any danger for bankruptcy at the moment.
- HROW has a better Altman-Z score (4.05) than 69.63% of its industry peers.
- HROW has a Debt/Equity ratio of 5.17. This is a high value indicating a heavy dependency on external financing.
- With a Debt to Equity ratio value of 5.17, HROW is not doing good in the industry: 81.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.05 |
ROIC/WACC0.77
WACC9.66%
2.3 Liquidity
- HROW has a Current Ratio of 2.72. This indicates that HROW is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of HROW (2.72) is comparable to the rest of the industry.
- HROW has a Quick Ratio of 2.52. This indicates that HROW is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of HROW (2.52) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
- HROW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.68%, which is quite impressive.
- HROW shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.83%.
- The Revenue has been growing by 31.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
3.2 Future
- HROW is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 72.94% yearly.
- HROW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.09% yearly.
EPS Next Y123.84%
EPS Next 2Y138.88%
EPS Next 3Y102.47%
EPS Next 5Y72.94%
Revenue Next Year39.77%
Revenue Next 2Y41.57%
Revenue Next 3Y40.21%
Revenue Next 5Y39.09%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- HROW is valuated quite expensively with a Price/Earnings ratio of 532.22.
- Based on the Price/Earnings ratio, HROW is valued a bit cheaper than 74.87% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.38. HROW is valued rather expensively when compared to this.
- The Price/Forward Earnings ratio is 29.37, which means the current valuation is very expensive for HROW.
- Based on the Price/Forward Earnings ratio, HROW is valued a bit cheaper than 73.30% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. HROW is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 532.22 | ||
| Fwd PE | 29.37 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HROW is valued a bit cheaper than 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 41.47 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- HROW has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as HROW's earnings are expected to grow with 102.47% in the coming years.
PEG (NY)4.3
PEG (5Y)N/A
EPS Next 2Y138.88%
EPS Next 3Y102.47%
5. Dividend
5.1 Amount
- No dividends for HROW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
47.9
-0.59 (-1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners58.38%
Inst Owner Change-0.07%
Ins Owners14.8%
Ins Owner Change7.79%
Market Cap1.77B
Revenue(TTM)250.04M
Net Income(TTM)-4.99M
Analysts85.71
Price Target72.13 (50.58%)
Short Float %17.94%
Short Ratio9.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)0%
PT rev (3m)14.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.84%
EPS NY rev (1m)112.83%
EPS NY rev (3m)-73.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.84%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-3.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 532.22 | ||
| Fwd PE | 29.37 | ||
| P/S | 7.1 | ||
| P/FCF | N/A | ||
| P/OCF | 99.27 | ||
| P/B | 37.74 | ||
| P/tB | N/A | ||
| EV/EBITDA | 41.47 |
EPS(TTM)0.09
EY0.19%
EPS(NY)1.63
Fwd EY3.4%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)0.48
OCFY1.01%
SpS6.75
BVpS1.27
TBVpS-3.43
PEG (NY)4.3
PEG (5Y)N/A
Graham Number1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.37% | ||
| ROE | -10.6% | ||
| ROCE | 9.46% | ||
| ROIC | 7.48% | ||
| ROICexc | 9.96% | ||
| ROICexgc | 45.18% | ||
| OM | 11.27% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% | ||
| FCFM | N/A |
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.24%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.18 | ||
| Cap/Depr | 207.09% | ||
| Cap/Sales | 15.46% | ||
| Interest Coverage | 1.19 | ||
| Cash Conversion | 38.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z | 4.05 |
F-Score7
WACC9.66%
ROIC/WACC0.77
Cap/Depr(3y)560.55%
Cap/Depr(5y)363.77%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
EPS Next Y123.84%
EPS Next 2Y138.88%
EPS Next 3Y102.47%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
Revenue Next Year39.77%
Revenue Next 2Y41.57%
Revenue Next 3Y40.21%
Revenue Next 5Y39.09%
EBIT growth 1Y428.64%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1305.78%
EBIT Next 3Y233.73%
EBIT Next 5Y132.11%
FCF growth 1Y87.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y308.55%
OCF growth 3YN/A
OCF growth 5YN/A
HARROW INC / HROW FAQ
Can you provide the ChartMill fundamental rating for HARROW INC?
ChartMill assigns a fundamental rating of 5 / 10 to HROW.
Can you provide the valuation status for HARROW INC?
ChartMill assigns a valuation rating of 3 / 10 to HARROW INC (HROW). This can be considered as Overvalued.
Can you provide the profitability details for HARROW INC?
HARROW INC (HROW) has a profitability rating of 6 / 10.
How financially healthy is HARROW INC?
The financial health rating of HARROW INC (HROW) is 4 / 10.
What is the expected EPS growth for HARROW INC (HROW) stock?
The Earnings per Share (EPS) of HARROW INC (HROW) is expected to grow by 123.84% in the next year.